Source:http://linkedlifedata.com/resource/pubmed/id/10673674
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2000-3-20
|
| pubmed:abstractText |
Respiratory syncytial virus (RSV) pneumonia in BMT recipients carries a mortality rate of approximately 50-70% despite ribavirin (Virazole) treatment. In both immunocompetent and immunocompromised animal models, RSV neutralizing antibodies rapidly reduce pulmonary virus load after a single dose. RSV-IGIV (RespiGam) is an IgG immune globulin with high concentrations of RSV neutralizing antibody (>19 200 MU/ml). From June 1991 to February 1996, a compassionate-use protocol using RSV-IGIV for treatment of RSV infections was conducted. Eleven children at multiple centers, mean age 3.3 years (4 months to 9 years), were undergoing BMT and met the protocol criteria. They received a single 1500 mg/kg dose of RSV-IGIV infused over 12 h at a median of 5 days (1-37 days) after RSV symptom onset. Ten of these patients received prior or concurrent aerosolized ribavirin. Serum RSV neutralizing titers were measured in five patients and showed a 3- to 30-fold increase 24 h after RSV-IGIV infusion. Adverse events were mild. One of 11 (9.1%) patients died from their RSV illness (91% RSV survival). In comparison to previously published reports, RSV-IGIV treatment of RSV pneumonia in BMT patients may increase survival above that in such patients treated with ribavirin alone. Bone Marrow Transplantation (2000) 25, 161-165.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulins, Intravenous,
http://linkedlifedata.com/resource/pubmed/chemical/Ribavirin,
http://linkedlifedata.com/resource/pubmed/chemical/respiratory syncytial virus immune...
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0268-3369
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
25
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
161-5
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:10673674-Administration, Inhalation,
pubmed-meshheading:10673674-Adult,
pubmed-meshheading:10673674-Antibodies, Viral,
pubmed-meshheading:10673674-Antiviral Agents,
pubmed-meshheading:10673674-Bone Marrow Transplantation,
pubmed-meshheading:10673674-Child,
pubmed-meshheading:10673674-Child, Preschool,
pubmed-meshheading:10673674-Clinical Protocols,
pubmed-meshheading:10673674-Combined Modality Therapy,
pubmed-meshheading:10673674-Humans,
pubmed-meshheading:10673674-Immunoglobulins, Intravenous,
pubmed-meshheading:10673674-Immunosuppression,
pubmed-meshheading:10673674-Infant,
pubmed-meshheading:10673674-Neutralization Tests,
pubmed-meshheading:10673674-Pneumonia, Viral,
pubmed-meshheading:10673674-Respiratory Syncytial Virus Infections,
pubmed-meshheading:10673674-Respiratory Syncytial Viruses,
pubmed-meshheading:10673674-Ribavirin,
pubmed-meshheading:10673674-Survival Rate,
pubmed-meshheading:10673674-Viral Load
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience.
|
| pubmed:affiliation |
University of Tennessee, Memphis, TN 38103, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study
|